• Very attractive area of immuno-oncology with renewed interest for innovative therapeutic vaccines approaches as illustrated by recent deals (several billion USD since 2013) and Series A rounds.
• A robust preclinical PoC, a First-in-human in melanoma and a candidate in phase I/II for lung cancer (potentially relevant for other cancer types)
• Disruptive and versatile technology platform with broad IP and rapid generation of clinical candidates in any cancer type and various tumor antigen types.
• First licensing deal signed in Asia with LG-Chem.
• Raised more than €61M in equity and non-dilutive money with last rounds led by the Asian leading VC KIP (Korean Investment Partners).
• Strong team with complementary academic and industrial track record.

PDC*line Pharma is preparing a 55 M€ Series C to fund:  

• A randomized Phase IIb clinical trial on 120 patients in NSCLC, 
• A phase Ib clinical trial with PDC*neo (with neoantigens) in colorectal cancer, 
• New generations of technology, including additional HLA such as HLA-A24, 
• New vaccines candidates for additional indications.  

By completing these activities, PDC*line Pharma aims to secure a major industrial deal in 2029 and pursue a potential IPO.